celecoxib has been researched along with Cancer of Mouth in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma." | 7.80 | Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. ( Ahn, JO; Coh, YR; Han, SM; Lee, HW; Rebhun, RB; Seo, KW; Youn, HY, 2014) |
| " Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma." | 3.80 | Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. ( Ahn, JO; Coh, YR; Han, SM; Lee, HW; Rebhun, RB; Seo, KW; Youn, HY, 2014) |
| "Platinum-resistant oral cancer has a dismal outcome with limited treatment options." | 2.90 | Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. ( Abraham, G; Banavali, S; Bhattacharjee, A; Chandrasekharan, A; Das, S; Dhumal, S; DSouza, H; Gota, V; Joshi, A; Kashyap, L; Kumar, S; Mahajan, A; Mahimkar, M; Menon, N; Mukadam, S; Nawale, K; Noronha, V; Pandey, M; Patil, VM; Prabhash, K; Sable, N; Simha, V; Solanki, B; Srinivas, S; Talreja, V, 2019) |
| "Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE(2), after 12 weeks." | 2.73 | A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. ( Bertagnolli, MM; Dorfman, DM; Goguen, L; Haddad, RI; Krane, JF; Li, Y; Moran, AE; Norris, CM; Othus, M; Posner, MR; Wirth, LJ, 2008) |
| "Celecoxib was generally well tolerated." | 2.73 | Pilot randomized phase II study of celecoxib in oral premalignant lesions. ( Atwell, A; Boyle, JO; Dannenberg, AJ; Du, B; El-Naggar, AK; Feng, L; Helman, JI; Lee, JJ; Lippman, SM; Nathan, CO; Ondrey, FG; Papadimitrakopoulou, VA; Peterson, DE; William, WN; Yueh, B, 2008) |
| "Inflammation is closely related to neoplastic development and the release of inflammatory cytokines and chemokines represents a crucial event in this relationship." | 1.51 | Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma. ( Antunes, DM; Corrêa, L; DE Oliveira, APL; Duarte, CME; Fernandes, KPS; Guimarães, DM; Miguita, L; Nunes, FD; Rodrigues, MFSD, 2019) |
| "Overexpression of cyclooxygenase-2 in oral cancer increases lymph node metastasis and is associated with a poor prognosis." | 1.46 | Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. ( Chang, PY; Chiang, SL; Chung, CM; Hua, CH; Ko, YC; Kuo, TM; Lin, SH; Tsai, MH; Velmurugan, BK; Wang, ZH; Yang, YH; Yeh, KT, 2017) |
| "Standard oral cancer therapy generally includes a combination of surgery with chemotherapy and/or radiotherapy." | 1.43 | A Chemopreventive Nanodiamond Platform for Oral Cancer Treatment. ( Daneshgaran, G; Ho, D; Kim, HJ; Yen, A; Zhang, K, 2016) |
| "Despite intensive investigation, oral squamous cell carcinomas (OSCC) represent a clinical challenge resulting in significant morbidity and mortality." | 1.42 | Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. ( Das, SK; Dash, R; Fisher, PB; Maji, S; Panda, S; Pattanaik, L; Pellecchia, M; Quinn, BA; Samal, SK; Sarkar, D, 2015) |
| "Pretreatment with celecoxib inhibited nicotine-induced change in the expression of VEGF and COX-2." | 1.38 | Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. ( Amanzadeh, A; Aslani, HR; Bidgoli, SA; Esfahani, M; Esfandiary, M; Ghahremani, MH; Habibzadeh, N; Salimi, M; Sedaghati, B, 2012) |
| "Oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide (NQO) show substantial overexpression of cyclooxygenase-2 (COX-2) when compared with adjacent phenotypically normal oral tissues." | 1.36 | Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. ( Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE, 2010) |
| "Celecoxib is a potent nonsteroid antiinflammatory drug (NSAID) that has shown great promise in cancer chemoprevention and treatment." | 1.33 | Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. ( Chen, CS; D'Ambrosio, SM; Ding, H; Han, C; Zhu, J, 2005) |
| "Celecoxib is a cyclooxygenase-2 inhibitor with significantly less toxicity." | 1.33 | Chemopreventive effect of celecoxib in oral precancers and cancers. ( Feng, L; Wang, Z, 2006) |
| "Celecoxib has a potential role for oral cancer chemoprevention but its systemic side effects are a concern." | 1.32 | Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. ( Polavaram, R; Shapshay, SM; Wang, Z, 2003) |
| "In this study, we used an oral squamous cell carcinoma cell line to study growth inhibition and changes in critical cell cycle-regulating proteins induced by the selective COX-2 inhibitor celecoxib." | 1.32 | Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma. ( Chau, M; Gilbert, R; Jordan, RC; Lim, MS; Lim, S; Mäkitie, AA; Viani, MA, 2003) |
| "Although all hamsters developed squamous cell carcinoma, the onset of tumor formation was delayed in a dose-dependent manner." | 1.32 | Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. ( Hashitani, S; Manno, Y; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2004) |
| "Celecoxib is a newly developed cyclo-oxygenase (COX)-2 inhibitor with significantly less toxicity." | 1.31 | Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. ( Fuentes, CF; Shapshay, SM; Wang, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (42.42) | 29.6817 |
| 2010's | 14 (42.42) | 24.3611 |
| 2020's | 5 (15.15) | 2.80 |
| Authors | Studies |
|---|---|
| Sultania, M | 5 |
| Imaduddin, M | 5 |
| S V Deo, S | 1 |
| Kar, M | 5 |
| K Muduly, D | 1 |
| Kumar, S | 2 |
| Sharma, A | 1 |
| Mishra, A | 1 |
| K D Majumdar, S | 1 |
| K Adhya, A | 1 |
| K Parida, D | 1 |
| Kamal, MV | 1 |
| Rao, M | 1 |
| Damerla, RR | 1 |
| Pai, A | 1 |
| Sharan, K | 1 |
| Palod, A | 1 |
| Shetty, PS | 1 |
| Usman, N | 1 |
| Kumar, NAN | 1 |
| Muduly, DK | 4 |
| Majumdar, SKD | 3 |
| Adhya, AK | 3 |
| Parida, DK | 3 |
| Patil, VM | 1 |
| Noronha, V | 2 |
| Joshi, A | 1 |
| Dhumal, S | 1 |
| Mahimkar, M | 1 |
| Bhattacharjee, A | 1 |
| Gota, V | 1 |
| Pandey, M | 1 |
| Menon, N | 1 |
| Mahajan, A | 1 |
| Sable, N | 1 |
| Nawale, K | 1 |
| Mukadam, S | 1 |
| Solanki, B | 1 |
| Das, S | 1 |
| Simha, V | 1 |
| Abraham, G | 1 |
| Chandrasekharan, A | 1 |
| Talreja, V | 1 |
| DSouza, H | 1 |
| Srinivas, S | 1 |
| Kashyap, L | 1 |
| Banavali, S | 1 |
| Prabhash, K | 2 |
| Gourd, E | 1 |
| Velmurugan, BK | 2 |
| Hua, CH | 2 |
| Tsai, MH | 2 |
| Lee, CP | 1 |
| Chung, CM | 2 |
| Ko, YC | 2 |
| Vigneshwaran, B | 1 |
| Chiang, SL | 1 |
| Lin, SH | 1 |
| Wang, ZH | 1 |
| Kuo, TM | 1 |
| Yeh, KT | 1 |
| Chang, PY | 1 |
| Yang, YH | 1 |
| Antunes, DM | 1 |
| Rodrigues, MFSD | 1 |
| Guimarães, DM | 1 |
| Duarte, CME | 1 |
| Miguita, L | 1 |
| Corrêa, L | 1 |
| DE Oliveira, APL | 1 |
| Fernandes, KPS | 1 |
| Nunes, FD | 1 |
| Liao, W | 1 |
| Yan, Y | 1 |
| Huang, Y | 1 |
| Li, W | 1 |
| Seo, KW | 1 |
| Coh, YR | 1 |
| Rebhun, RB | 1 |
| Ahn, JO | 1 |
| Han, SM | 1 |
| Lee, HW | 1 |
| Youn, HY | 1 |
| Qian, M | 1 |
| Qian, D | 1 |
| Jing, H | 1 |
| Li, Y | 2 |
| Ma, C | 1 |
| Zhou, Y | 1 |
| Maji, S | 1 |
| Samal, SK | 1 |
| Pattanaik, L | 1 |
| Panda, S | 1 |
| Quinn, BA | 1 |
| Das, SK | 1 |
| Sarkar, D | 1 |
| Pellecchia, M | 1 |
| Fisher, PB | 1 |
| Dash, R | 1 |
| Yen, A | 1 |
| Zhang, K | 1 |
| Daneshgaran, G | 1 |
| Kim, HJ | 1 |
| Ho, D | 1 |
| Wirth, LJ | 1 |
| Krane, JF | 1 |
| Othus, M | 1 |
| Moran, AE | 1 |
| Dorfman, DM | 1 |
| Norris, CM | 1 |
| Goguen, L | 1 |
| Posner, MR | 1 |
| Haddad, RI | 1 |
| Bertagnolli, MM | 1 |
| Leem, DH | 1 |
| Choi, KH | 1 |
| Han, HS | 1 |
| Kim, JH | 1 |
| Shin, JA | 1 |
| Choi, ES | 1 |
| Shim, JH | 1 |
| Kong, G | 1 |
| Min, YK | 1 |
| Nam, JS | 1 |
| Oh, SH | 1 |
| Kim, KA | 1 |
| Kwon, KH | 1 |
| Cho, NP | 1 |
| Cho, SD | 1 |
| McCormick, DL | 1 |
| Phillips, JM | 1 |
| Horn, TL | 1 |
| Johnson, WD | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Yan, YX | 1 |
| Li, WZ | 1 |
| Huang, YQ | 1 |
| Liao, WX | 1 |
| Patil, V | 1 |
| D'cruz, AK | 1 |
| Banavali, SD | 1 |
| Salimi, M | 1 |
| Esfahani, M | 1 |
| Habibzadeh, N | 1 |
| Aslani, HR | 1 |
| Amanzadeh, A | 1 |
| Esfandiary, M | 1 |
| Sedaghati, B | 1 |
| Bidgoli, SA | 1 |
| Ghahremani, MH | 1 |
| Wang, Z | 4 |
| Fuentes, CF | 2 |
| Shapshay, SM | 3 |
| Mohan, S | 1 |
| Epstein, JB | 1 |
| Polavaram, R | 1 |
| Mäkitie, AA | 1 |
| Chau, M | 1 |
| Lim, S | 1 |
| Viani, MA | 1 |
| Gilbert, R | 1 |
| Lim, MS | 1 |
| Jordan, RC | 1 |
| Terakado, N | 1 |
| Shintani, S | 1 |
| Yano, J | 1 |
| Chunnan, L | 1 |
| Mihara, M | 1 |
| Nakashiro, K | 1 |
| Hamakawa, H | 1 |
| Nishimura, N | 1 |
| Urade, M | 1 |
| Hashitani, S | 1 |
| Noguchi, K | 1 |
| Manno, Y | 1 |
| Takaoka, K | 1 |
| Sakurai, K | 1 |
| Ding, H | 1 |
| Han, C | 1 |
| Zhu, J | 1 |
| Chen, CS | 1 |
| D'Ambrosio, SM | 1 |
| Li, N | 1 |
| Sood, S | 1 |
| Wang, S | 1 |
| Fang, M | 1 |
| Wang, P | 1 |
| Sun, Z | 1 |
| Yang, CS | 1 |
| Chen, X | 1 |
| Nelson, NJ | 1 |
| Couzin, J | 1 |
| Schirber, M | 1 |
| Feng, L | 2 |
| Papadimitrakopoulou, VA | 1 |
| William, WN | 1 |
| Dannenberg, AJ | 1 |
| Lippman, SM | 1 |
| Lee, JJ | 1 |
| Ondrey, FG | 1 |
| Peterson, DE | 1 |
| Atwell, A | 1 |
| El-Naggar, AK | 1 |
| Nathan, CO | 1 |
| Helman, JI | 1 |
| Du, B | 1 |
| Yueh, B | 1 |
| Boyle, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions[NCT00014404] | Phase 2 | 0 participants | Interventional | 2000-10-31 | Completed | ||
| Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention[NCT01192204] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number. (NCT01192204)
Timeframe: pretreatment and posttreatment (3 months treatment duration)
| Intervention | mm^2 (Mean) |
|---|---|
| 10% FBR Gel | -26.12 |
| Placebo Gel | 18.12 |
Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes. (NCT01192204)
Timeframe: Before and after the 3 month treatment duration
| Intervention | LOH events (Mean) |
|---|---|
| 10% FBR Gel | 0.9 |
| Placebo Gel | 0.4 |
A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME). (NCT01192204)
Timeframe: Before and after the 3 month treatment.
| Intervention | unit on histologic grade scale (Mean) | |
|---|---|---|
| Pretreatment | Posttreatment | |
| 10% FBR Gel | 2.36 | 1.9 |
| Placebo Gel | 2.83 | 2.58 |
2 reviews available for celecoxib and Cancer of Mouth
| Article | Year |
|---|---|
A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Head and Neck N | 2023 |
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous | 2003 |
3 trials available for celecoxib and Cancer of Mouth
| Article | Year |
|---|---|
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; | 2019 |
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
28 other studies available for celecoxib and Cancer of Mouth
| Article | Year |
|---|---|
Role of metronomic therapy for advanced oral cancers and predictors of response: Multi-institutional feasibility study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide; Feasibility Studies; Hu | 2022 |
Metronomic Therapy in Palliation of Oral Cancer Patients-A Home Based Approach at the End of Life.
Topics: Celecoxib; Death; Humans; Methotrexate; Middle Aged; Mouth Neoplasms; Palliative Care; Prospective S | 2022 |
Metronomic Therapy in Palliation of Oral Cancer Patients-A Home Based Approach at the End of Life.
Topics: Celecoxib; Death; Humans; Methotrexate; Middle Aged; Mouth Neoplasms; Palliative Care; Prospective S | 2022 |
Metronomic Therapy in Palliation of Oral Cancer Patients-A Home Based Approach at the End of Life.
Topics: Celecoxib; Death; Humans; Methotrexate; Middle Aged; Mouth Neoplasms; Palliative Care; Prospective S | 2022 |
Metronomic Therapy in Palliation of Oral Cancer Patients-A Home Based Approach at the End of Life.
Topics: Celecoxib; Death; Humans; Methotrexate; Middle Aged; Mouth Neoplasms; Palliative Care; Prospective S | 2022 |
Metronomic chemotherapy option for advanced oral cancer.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Ce | 2019 |
Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Topics: Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2020 |
Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
Topics: Carcinoma; Celecoxib; Cisplatin; COVID-19; Humans; Methotrexate; Mouth Neoplasms; Neoplasm Recurrenc | 2021 |
Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma.
Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous | 2017 |
Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tu | 2019 |
[Celecoxib enhances chemosensitivity of oral cancer cells by blocking cell cycle progression in vitro].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Cycle; Cell Line, Tumor; Cy | 2013 |
Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
Topics: Animals; Blotting, Western; Celecoxib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; | 2014 |
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Ce | 2014 |
Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Prote | 2015 |
A Chemopreventive Nanodiamond Platform for Oral Cancer Treatment.
Topics: Anticarcinogenic Agents; Celecoxib; Chemoprevention; Cyclooxygenase 2 Inhibitors; Delayed-Action Pre | 2016 |
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation | 2010 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expr | 2010 |
The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Prol | 2012 |
Metronomic chemotherapy in advanced oral cancers.
Topics: Administration, Metronomic; Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Celeco | 2012 |
Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenas | 2012 |
Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Celecoxib; Cell Di | 2002 |
Cancer "photo-chemoprevention" with pulsed dye laser and celecoxib.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Combined Modality Therapy; Disease Mo | 2003 |
Topical inhibition of oral carcinoma cell with polymer delivered celecoxib.
Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase Inhibitors; Humans | 2003 |
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Surviva | 2003 |
Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; | 2004 |
Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; C | 2004 |
Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; Cardiovascular Diseases; Caspase 9; Caspase | 2005 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogen | 2005 |
Years of research come to fruition with launch of oral cancer prevention trial.
Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenas | 2006 |
Scientific misconduct. Fraud upends oral cancer field, casting doubt on prevention trial.
Topics: Aneuploidy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Disease Su | 2006 |
Chemopreventive effect of celecoxib in oral precancers and cancers.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Celecoxib; Chemopreven | 2006 |